HIV-1

• 

  Subject Areas on Research

  • 2'-O-Methylation can increase the abundance and lifetime of alternative RNA conformational states. 
  • 4-oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. 
  • 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. 
  • A Computational Model of Inhibition of HIV-1 by Interferon-Alpha. 
  • A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. 
  • A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. 
  • A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. 
  • A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. 
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. 
  • A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. 
  • A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. 
  • A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. 
  • A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. 
  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. 
  • A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. 
  • A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. 
  • A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. 
  • A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo. 
  • A general method for constructing atomic-resolution RNA ensembles using NMR residual dipolar couplings: the basis for interhelical motions revealed. 
  • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. 
  • A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. 
  • A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. 
  • A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. 
  • A human anti-HIV autoantibody enhances EBV transformation and HIV infection. 
  • A human recombinant Fab identifies a human immunodeficiency virus type 1-induced conformational change in cell surface-expressed CD4. 
  • A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody. 
  • A model for alignment of Env V1 and V2 hypervariable domains from human and simian immunodeficiency viruses. 
  • A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. 
  • A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence. 
  • A new entry route for HIV. 
  • A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. 
  • A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. 
  • A nuclear role for the Fragile X mental retardation protein. 
  • A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. 
  • A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. 
  • A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). 
  • A plea for justice for jailed medical workers. 
  • A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro. 
  • A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. 
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. 
  • A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. 
  • A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. 
  • A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. 
  • A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. 
  • A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. 
  • A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. 
  • A single gp120 residue can affect HIV-1 tropism in macaques. 
  • A single, continuous metric to define tiered serum neutralization potency against HIV. 
  • A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. 
  • A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. 
  • A soluble inhibitor of T lymphocyte function induced by HIV-1 infection of CD4+ T cells: characterization of a cellular protein and its relationship to p15E. 
  • A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. 
  • A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. 
  • A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. 
  • A whole-genome association study of major determinants for host control of HIV-1. 
  • ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. 
  • AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition. 
  • AIDS. The positive effect of the negative factor. 
  • AIDS. Where has HIV been hiding? 
  • AIDS/HIV. Host controls of HIV neutralizing antibodies. 
  • AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. 
  • AZT inhibits HIV-1 replication in monocytes. 
  • Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. 
  • Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. 
  • Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. 
  • Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. 
  • Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit. 
  • Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. 
  • Acetylation of Cytidine Residues Boosts HIV-1 Gene Expression by Increasing Viral RNA Stability. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Activation of tat-defective human immunodeficiency virus by ultraviolet light. 
  • Acute Dengue fever causes false-positive reactivity in OraQuick rapid HIV-1/2 antibody test. 
  • Acute HIV-1 Infection. 
  • Acute HIV-1 infection in the Southeastern United States: a cohort study. 
  • Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants. 
  • Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics? 
  • Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. 
  • Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. 
  • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. 
  • Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. 
  • Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. 
  • Aggregate complexes of HIV-1 induced by multimeric antibodies. 
  • Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. 
  • Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. 
  • Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. 
  • Alterations of the B-cell response by HIV-1 replication. 
  • Alternative approaches for the application of ribozymes as gene therapies for retroviral infections. 
  • Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. 
  • Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev. 
  • Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurologic disease. 
  • Amplification of a complete simian immunodeficiency virus genome from fecal RNA of a wild chimpanzee. 
  • Amplification of human immunodeficiency virus provirus from cerebrospinal fluid: results of long-term clinical follow-up. 
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. 
  • An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses. 
  • An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein. 
  • An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials. 
  • An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. 
  • An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. 
  • An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. 
  • An in vitro transcription system that recapitulates equine infectious anemia virus tat-mediated inhibition of human immunodeficiency virus type 1 Tat activity demonstrates a role for positive transcription elongation factor b and associated proteins in the mechanism of Tat activation. 
  • An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. 
  • An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. 
  • Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. 
  • Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. 
  • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. 
  • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. 
  • Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. 
  • Analysis of the T-cell receptor beta-chain variable-region (V beta) repertoire in monozygotic twins discordant for human immunodeficiency virus: evidence for perturbations of specific V beta segments in CD4+ T cells of the virus-positive twins. 
  • Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. 
  • Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. 
  • Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates. 
  • Analysis of the interaction of primate retroviruses with the human RNA interference machinery. 
  • Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. 
  • Ancestral and consensus envelope immunogens for HIV-1 subtype C. 
  • Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid. 
  • Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents. 
  • Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. 
  • Anti-AIDS agents 85. Design, synthesis, and evaluation of 1R,2R-dicamphanoyl-3,3-dimethyldihydropyrano-[2,3-c]xanthen-7(1H)-one (DCX) derivatives as novel anti-HIV agents. 
  • Anti-AIDS agents 86. Synthesis and anti-HIV evaluation of 2',3'-seco-3'-nor DCP and DCK analogues. 
  • Anti-AIDS agents 87. New bio-isosteric dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-khellactone (DCK) analogues with potent anti-HIV activity. 
  • Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. 
  • Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. 
  • Anti-AIDS agents. 15. Synthesis and anti-HIV activity of dihydroseselins and related analogs. 
  • Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents. 
  • Anti-AIDS agents. 42. Synthesis and anti-HIV activity of disubstituted (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone analogues. 
  • Anti-AIDS agents. 60. Substituted 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents. 
  • Anti-Acids Agents, 6. Salaspermic Acid, an Anti-HIV Principle from Tripterygium Wilfordii, and the Structure Activity Correlation with Its Related Compounds 
  • Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. 
  • Anti-HIV-1 ADCC: clinical and therapeutic implications. 
  • Anti-inflammatory and Anti-HIV Compounds from Swertia bimaculata. 
  • Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. 
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. 
  • Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. 
  • Antibodies for prevention of mother-to-child transmission of HIV-1. 
  • Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. 
  • Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. 
  • Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. 
  • Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. 
  • Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. 
  • Antibody polyspecificity and neutralization of HIV-1: a hypothesis. 
  • Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. 
  • Antibody responses to the HIV-1 envelope high mannose patch. 
  • Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. 
  • Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. 
  • Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. 
  • Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. 
  • Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. 
  • Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. 
  • Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. 
  • Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannosidase I and II inhibitors. 
  • Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. 
  • Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. 
  • Antifusion activity in sera from persons infected with human immunodeficiency virus type 1. 
  • Antigen-specific NK cell memory in rhesus macaques. 
  • Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. 
  • Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. 
  • Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate. 
  • Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. 
  • Antiretroviral drug resistance among treatment-naïve HIV-1-infected persons in Washington, D.C. 
  • Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. 
  • Antiretroviral preexposure prophylaxis for HIV prevention. 
  • Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells. 
  • Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. 
  • Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents. 
  • Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. 
  • Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. 
  • Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. 
  • Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. 
  • Approaches to HIV vaccine design. 
  • Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. 
  • Appropriate use of nevirapine for long-term therapy. 
  • Argininamide binding arrests global motions in HIV-1 TAR RNA: comparison with Mg2+-induced conformational stabilization. 
  • Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation. 
  • Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. 
  • Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. 
  • Association of HIV-infection, antiretroviral treatment and metabolic syndrome with large artery stiffness: a cross-sectional study. 
  • Association of cervical biopsy with HIV type 1 genital shedding among women on highly active antiretroviral therapy. 
  • Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. 
  • Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene. 
  • Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. 
  • Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. 
  • Authors' reply: Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study: population and statistical queries. 
  • Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. 
  • B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses. 
  • B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. 
  • B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. 
  • Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. 
  • Behavioral and demographic risk factors for transmission of human immunodeficiency virus type 1 in heterosexual couples: report from the Heterosexual HIV Transmission Study. 
  • Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. 
  • Betulinic acid derivatives as HIV-1 antivirals. 
  • Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. 
  • Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. 
  • Beyond Viral Neutralization. 
  • Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. 
  • Bioactive ent-isopimarane diterpenoids from Euphorbia neriifolia. 
  • Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins. International Registry of HIV-Exposed Twins. 
  • Bispecific Antibodies Against HIV. 
  • Blocking HIV-1 entry by a gp120 surface binding inhibitor. 
  • Bone marrow cultures for the diagnosis of mycobacterial and fungal infections in patients infected with the human immunodeficiency virus. 
  • Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. 
  • Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. 
  • Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. 
  • Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. 
  • Bringing the path toward an HIV-1 vaccine into focus. 
  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 
  • Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India. 
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. 
  • Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. 
  • Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. 
  • Broadly neutralizing monoclonal antibodies for HIV prevention. 
  • CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription. 
  • CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. 
  • CCL3L1 and HIV/AIDS susceptibility. 
  • CCR5del32 in perinatal HIV-1 infection. 
  • CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. 
  • CD4 mimetics sensitize HIV-1-infected cells to ADCC. 
  • CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. 
  • CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children. 
  • CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. 
  • CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. 
  • CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. 
  • CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. 
  • CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. 
  • CD8(+)T-cell-mediated control of HIV-1 and SIV infection. 
  • CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. 
  • CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. 
  • CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. 
  • CD8+ T cells: mechanistic target of rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control. 
  • CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. 
  • CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. 
  • COMPASS identifies T-cell subsets correlated with clinical outcomes. 
  • CSF, plasma viral load and HIV associated dementia. 
  • CTL cross reactivity between HIV strains. 
  • Can the thymus win the battle against drug-resistant HIV? 
  • Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. 
  • Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. 
  • Capacity of health-care facilities to deliver HIV treatment and care services, Northern Tanzania, 2004. 
  • Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. 
  • Carbazole Alkaloids from Clausena anisum-olens: Isolation, Characterization, and Anti-HIV Evaluation. 
  • Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. 
  • Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism. 
  • Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. 
  • Cellular fatty acid synthase is required for late stages of HIV-1 replication. 
  • Cellular immune response to viral peptides in patients exposed to HIV. 
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. 
  • Centralized HIV-1 envelope immunogens and neutralizing antibodies. 
  • Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. 
  • Change point testing in logistic regression models with interaction term. 
  • Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. 
  • Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. 
  • Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. 
  • Changes in neuropsychological functioning with progression of HIV-1 infection: results of an 8-year longitudinal investigation. 
  • Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. 
  • Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. 
  • Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. 
  • Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. 
  • Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. 
  • Characterization of a trimeric MPER containing HIV-1 gp41 antigen. 
  • Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. 
  • Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. 
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. 
  • Characterization of primary isolate-like variants of simian-human immunodeficiency virus. 
  • Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques. 
  • Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use. 
  • Characterizing RNA Excited States Using NMR Relaxation Dispersion. 
  • Characterizing complex dynamics in the transactivation response element apical loop and motional correlations with the bulge by NMR, molecular dynamics, and mutagenesis. 
  • Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. 
  • Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. 
  • Chemokine receptors and human immunodeficiency virus infection. 
  • Chronic ethanol intoxication enhances the production of cytokine-induced neutrophil chemoattractant and macrophage inflammatory protein-2 by hepatocytes after human immunodeficiency virus-1 glycoprotein 120 vaccination. 
  • Chronicity and remission of fatigue in patients with established HIV infection. 
  • Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. 
  • Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. 
  • Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. 
  • Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. 
  • Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. 
  • Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. 
  • Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. 
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 
  • Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. 
  • Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. 
  • Coarse grained models reveal essential contributions of topological constraints to the conformational free energy of RNA bulges. 
  • Cobalamin inhibition of HIV-1 integrase and integration of HIV-1 DNA into cellular DNA. 
  • Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. 
  • Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. 
  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression. 
  • Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. 
  • Common genetic variation and the control of HIV-1 in humans. 
  • Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. 
  • Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. 
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. 
  • Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. 
  • Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. 
  • Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2. 
  • Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C. 
  • Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. 
  • Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. 
  • Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. 
  • Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. 
  • Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. 
  • Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. 
  • Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. 
  • Comparison of blood collected in acid-citrate-dextrose and EDTA for use in human immunodeficiency virus peripheral blood mononuclear cell cultures. 
  • Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. 
  • Comparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assays. 
  • Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques. 
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. 
  • Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. 
  • Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. 
  • Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. 
  • Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). 
  • Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. 
  • Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). 
  • Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. 
  • Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. 
  • Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. 
  • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. 
  • Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. 
  • Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. 
  • Complex immune correlates of protection in HIV-1 vaccine efficacy trials. 
  • Complications and Route of Delivery in a Large Cohort Study of HIV-1-Infected Women-IMPAACT P1025. 
  • Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China. 
  • Computational analysis of antibody dynamics identifies recent HIV-1 infection. 
  • Computational separation of conformational heterogeneity using cryo-electron tomography and 3D sub-volume averaging. 
  • Concerted motions in HIV-1 TAR RNA may allow access to bound state conformations: RNA dynamics from NMR residual dipolar couplings. 
  • Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. 
  • Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group. 
  • Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. 
  • Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF. 
  • Conjugates of betulin derivatives with AZT as potent anti-HIV agents. 
  • Consensus and ancestral state HIV vaccines. 
  • Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins. 
  • Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. 
  • Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: corrections and clarifications. 
  • Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications. 
  • Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. 
  • Constructing RNA dynamical ensembles by combining MD and motionally decoupled NMR RDCs: new insights into RNA dynamics and adaptive ligand recognition. 
  • Constructing atomic-resolution RNA structural ensembles using MD and motionally decoupled NMR RDCs. 
  • Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 
  • Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. 
  • Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination. 
  • Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8+ T cells in HIV-1 infection. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges. 
  • Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. 
  • Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. 
  • Coping strategies and patterns of alcohol and drug use among HIV-infected patients in the United States Southeast. 
  • Copy number variation of KIR genes influences HIV-1 control. 
  • Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. 
  • Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. 
  • Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. 
  • Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. 
  • Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. 
  • Country Level Diversity of the HIV-1 Pandemic between 1990 and 2015. 
  • Coupled in vitro synthesis and splicing of RNA polymerase II transcripts. 
  • Crescentic IgA nephropathy and acute renal failure in an HIV-positive patient with enteric salmonella infection. 
  • Critical issues in mucosal immunity for HIV-1 vaccine development. 
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. 
  • Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. 
  • Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. 
  • Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. 
  • Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. 
  • Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. 
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. 
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. 
  • Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. 
  • Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. 
  • Cross-reactivity of HIV vaccine responses and the microbiome. 
  • Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. 
  • Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. 
  • Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. 
  • Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. 
  • Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. 
  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. 
  • Curing HIV: Seeking to Target and Clear Persistent Infection. 
  • Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. 
  • Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity. 
  • Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Cytomegalovirus retinitis in HIV-infected patients with elevated CD4+ counts. 
  • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. 
  • DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. 
  • DNA biochip using a phototransistor integrated circuit. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. 
  • Daphneodorins A-C, Anti-HIV Gnidimacrin Related Macrocyclic Daphnane Orthoesters from Daphne odora. 
  • Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. 
  • Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. 
  • Defensins: natural anti-HIV peptides. 
  • Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. 
  • Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. 
  • Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. 
  • Demonstration that Small Molecules can Bind and Stabilize Low-abundance Short-lived RNA Excited Conformational States. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. 
  • Derivation of a biologically contained replication system for human immunodeficiency virus type 1. 
  • Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors. 
  • Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. 
  • Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group. 
  • Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. 
  • Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. 
  • Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration. 
  • Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease. 
  • Design, synthesis and structure relationships of new N,N',N",N"'-tetrakis (omega-amino alkyl) tetraazamacrocycles. 
  • Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. 
  • Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. 
  • Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors. 
  • Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. 
  • Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. 
  • Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. 
  • Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network. 
  • Detection of bloodstream pathogens in a bacille Calmette-Guérin (BCG)-vaccinated pediatric population in Malawi: a pilot study. 
  • Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. 
  • Detection of human immunodeficiency virus type 1 DNA sequence using plasmonics nanoprobes. 
  • Detection of mucosal antibodies in HIV type 1-infected individuals. 
  • Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. 
  • Determinants of Tenascin-C and HIV-1 envelope binding and neutralization. 
  • Determination of molecular structures of HIV envelope glycoproteins using cryo-electron tomography and automated sub-tomogram averaging. 
  • Determination of neutralization activities by a new versatile assay using an HIV-1 genome carrying the Gaussia luciferase gene. 
  • Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. 
  • Development and validation of an electronic medical record (EMR)-based computed phenotype of HIV-1 infection. 
  • Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. 
  • Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. 
  • Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. 
  • Development of a novel screen for protease inhibitors. 
  • Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. 
  • Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. 
  • Development of a vaccine for the prevention of AIDS, a critical appraisal. 
  • Development of an env gp41-based heteroduplex mobility assay for rapid human immunodeficiency virus type 1 subtyping. 
  • Development of an international external quality assurance program for HIV-1 incidence using the Limiting Antigen Avidity assay. 
  • Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. 
  • Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. 
  • Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity. 
  • Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. 
  • Dicistronic polioviruses as expression vectors for foreign genes. 
  • Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. 
  • Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses. 
  • Differential inhibition of HIV-1 cell binding and HIV-1-induced syncytium formation by low molecular weight sulphated polysaccharides. 
  • Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. 
  • Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. 
  • Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. 
  • Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. 
  • Direct and indirect estimates of HIV-1 incidence in a high-prevalence population. 
  • Direct interactions between autoantigen La and human immunodeficiency virus leader RNA. 
  • Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity. 
  • Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. 
  • Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. 
  • Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. 
  • Disparities in Depressive Symptoms and Antidepressant Treatment by Gender and Race/Ethnicity among People Living with HIV in the United States. 
  • Disparities in viral load and CD4 count trends among HIV-infected adults in South Carolina. 
  • Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. 
  • Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. 
  • Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. 
  • Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. 
  • Distinctive gene transduction efficiencies of commonly used viral vectors in the retina. 
  • Distinctive variation in the U3R region of the 5' Long Terminal Repeat from diverse HIV-1 strains. 
  • Diterpenes from the stem bark of Euphorbia neriifolia and their in vitro anti-HIV activity. 
  • Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. 
  • Diversity considerations in HIV-1 vaccine selection. 
  • Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. 
  • Does HIV-1 Tat induce a change in viral initiation rights? 
  • Does RNA interference have a future as a treatment for HIV-1 induced disease? 
  • Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain? 
  • Domain-elongation NMR spectroscopy yields new insights into RNA dynamics and adaptive recognition. 
  • Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Drug susceptibility and resistance mutations after first-line failure in resource limited settings. 
  • Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. 
  • Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. 
  • Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. 
  • Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. 
  • Dual tropism of HIV-1 envelopes derived from renal tubular epithelial cells of patients with HIV-associated nephropathy. 
  • Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. 
  • Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. 
  • Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. 
  • Durhamycin A, a potent inhibitor of HIV Tat transactivation. 
  • Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. 
  • Dynamic ensemble of HIV-1 RRE stem IIB reveals non-native conformations that disrupt the Rev-binding site. 
  • Dynamic motions of the HIV-1 frameshift site RNA. 
  • Dysregulation of mitochondrial bioenergetics and quality control by HIV-1 Tat in cardiomyocytes. 
  • Early Life HIV-1 Immunization: Providing a Window for Protection Before Sexual Debut. 
  • Early intensification with abacavir in subjects at high risk for incomplete viral suppression. 
  • Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. 
  • Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. 
  • Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. 
  • Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. 
  • Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. 
  • Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. 
  • Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission. 
  • Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5. 
  • Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. 
  • Effect of smoking on the clinical progression of HIV-1 infection. 
  • Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. 
  • Effective inactivation of human immunodeficiency virus with chlorhexidine antiseptics containing detergents and alcohol. 
  • Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells. 
  • Effects of chimeric mutants of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex on nucleolar targeting signals. 
  • Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. 
  • Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. 
  • Effects of human immunodeficiency virus type 1 on CD4 lymphocyte subset activation. 
  • Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients. 
  • Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. 
  • Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. 
  • Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. 
  • Efficient polyadenylation within the human immunodeficiency virus type 1 long terminal repeat requires flanking U3-specific sequences. 
  • Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. 
  • Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. 
  • Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 
  • Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. 
  • Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. 
  • Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. 
  • Endogenous opioids and HIV infection. 
  • Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Engineering antibody-based molecules for HIV treatment and cure. 
  • Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. 
  • Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24. 
  • Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein. 
  • Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. 
  • Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. 
  • Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. 
  • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. 
  • Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. 
  • Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. 
  • Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). 
  • Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. 
  • Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains. 
  • Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. 
  • Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. 
  • Enzyme immunoassay for detection of human immunodeficiency virus-specific immunoglobulin A antibodies. 
  • Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. 
  • Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication. 
  • Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. 
  • Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. 
  • Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. 
  • Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. 
  • Epitranscriptomic Addition of m5C to HIV-1 Transcripts Regulates Viral Gene Expression. 
  • Epitranscriptomic addition of m6A regulates HIV-1 RNA stability and alternative splicing. 
  • Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. 
  • Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. 
  • Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. 
  • Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. 
  • Estimation and prediction with HIV-treatment interruption data. 
  • Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. 
  • Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities. 
  • Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). 
  • Evaluation of an atypical HIV type 1 antibody. Serologic pattern leading to detection of HIV type 2 infection in North America. 
  • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. 
  • Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. 
  • Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. 
  • Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. 
  • Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. 
  • Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. 
  • Evidence for susceptibility of intrathymic T cell precursors to human immunodeficiency virus infection: a mechanism for T4 (CD4) lymphocyte depletion. 
  • Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha beta + and TCR gamma delta + to human immunodeficiency virus infection: a mechanism for CD4+ (T4) lymphocyte depletion. 
  • Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. 
  • Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. 
  • Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. 
  • Evidence that electrostatic interactions dictate the ligand-induced arrest of RNA global flexibility. 
  • Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. 
  • Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. 
  • Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. 
  • Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. 
  • Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. 
  • Exposing Hidden High-Affinity RNA Conformational States. 
  • Expression levels of TLRs involved in viral recognition in PBMCs from HIV-1-infected patients failing antiretroviral therapy. 
  • Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. 
  • Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. 
  • Extensive recombination due to heteroduplexes generates large amounts of artificial gene fragments during PCR. 
  • External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations. 
  • External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges. 
  • FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy. 
  • FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. 
  • Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. 
  • Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. 
  • Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. 
  • Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. 
  • Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation. 
  • Failure to identify human immunodeficiency virus-seropositive newborns: epidemiology and enrollment patterns in a predominantly white, nonurban setting. 
  • False-positivity of HIV-2 immunoblots in a cohort of elite suppressors infected with HIV-1. 
  • Fast Dissemination of New HIV-1 CRF02/A1 Recombinants in Pakistan. 
  • Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. 
  • Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. 
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. 
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. 
  • Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. 
  • Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. 
  • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. 
  • Frequency of atazanavir-associated leukocyturia development and renal function decline. 
  • Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. 
  • Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. 
  • Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. 
  • Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. 
  • Functional characterization of a complex protein-DNA-binding domain located within the human immunodeficiency virus type 1 long terminal repeat leader region. 
  • Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species. 
  • Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev. 
  • Functional differences between human and bovine immunodeficiency virus Tat transcription factors. 
  • Functional domain organization of human APOBEC3G. 
  • Functional interrogation and mining of natively paired human VH:VL antibody repertoires. 
  • Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators. 
  • Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). 
  • Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. 
  • Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. 
  • Functions of the auxiliary gene products of the human immunodeficiency virus type 1. 
  • Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. 
  • GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. 
  • GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. 
  • Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting. 
  • Gene Editing: A New Tool for Viral Disease. 
  • Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. 
  • Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. 
  • Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. 
  • Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis. 
  • Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. 
  • Generation of random mutant libraries with multiple primers in a single reaction. 
  • Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. 
  • Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. 
  • Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. 
  • Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. 
  • Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. 
  • Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. 
  • Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus. 
  • Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. 
  • Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. 
  • Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA [corrected]. 
  • Genetic risk factors for perinatally acquired HIV-1 infection. 
  • Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. 
  • Genetic variability of the U5 and downstream sequence of major HIV-1 subtypes and circulating recombinant forms. 
  • Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. 
  • Genetically and epidemiologically related "non-syncytium-inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. 
  • Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. 
  • Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. 
  • Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. 
  • Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey. 
  • Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. 
  • Global dimensions of the AIDS epidemic: implications for prevention and care. 
  • Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. 
  • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. 
  • Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. 
  • Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. 
  • Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. 
  • Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. 
  • Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β. 
  • Gonococcal lipooligosaccharide suppresses HIV infection in human primary macrophages through induction of innate immunity. 
  • Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. 
  • Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. 
  • Growth patterns reflect response to antiretroviral therapy in HIV-positive infants: potential utility in resource-poor settings. 
  • Gut microbes out of control in HIV infection. 
  • HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. 
  • HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. 
  • HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania. 
  • HIV antibodies for treatment of HIV infection. 
  • HIV entry inhibitors: progress in development and application. 
  • HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. 
  • HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. 
  • HIV heterosexual transmission: a hypothesis about an additional potential determinant. 
  • HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. 
  • HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression. 
  • HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. 
  • HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. 
  • HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. 
  • HIV vaccine development at Duke University Medical Center. 
  • HIV vaccine development: perspective. 
  • HIV vaccines. Magic of the occult? 
  • HIV vaccines: where we are and where we are going. 
  • HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. 
  • HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. 
  • HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. 
  • HIV-1 Drug Resistance and Virologic Outcomes Among Tanzanian Youth Living With HIV. 
  • HIV-1 Envelope Conformation, Allostery, and Dynamics. 
  • HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. 
  • HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. 
  • HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication. 
  • HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. 
  • HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. 
  • HIV-1 Nef protein: An invitation to a kill. 
  • HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. 
  • HIV-1 Packing to Leave. 
  • HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. 
  • HIV-1 Rev promotes the nuclear export of unspliced and singly spliced RNAs in a mammalian cell-free export system. 
  • HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. 
  • HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. 
  • HIV-1 Vif: counteracting innate antiretroviral defenses. 
  • HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells. 
  • HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. 
  • HIV-1 activates macrophages independent of Toll-like receptors. 
  • HIV-1 and HIV-Associated Nephropathy 25 Years Later. 
  • HIV-1 antibodies and vaccine antigen selectively interact with lipid domains. 
  • HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. 
  • HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? 
  • HIV-1 auxiliary proteins: making connections in a dying cell. 
  • HIV-1 diversity and compartmentalization in urine, semen, and blood. 
  • HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. 
  • HIV-1 dynamics in haemodialysis patients. 
  • HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
  • HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. 
  • HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. 
  • HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. 
  • HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. 
  • HIV-1 fitness and macrophages. 
  • HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. 
  • HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. 
  • HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. 
  • HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. 
  • HIV-1 hides an Achilles' heel in virion lipids. 
  • HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. 
  • HIV-1 infected women and prenatal care utilization: barriers and facilitators. 
  • HIV-1 infection in the lymphoid organs. 
  • HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. 
  • HIV-1 infection of human T lymphocytes results in enhanced alpha 5 beta 1 integrin expression. 
  • HIV-1 infection of the kidney: mechanisms and implications. 
  • HIV-1 infection stimulates T cell invasiveness and synthesis of the 92-kDa type IV collagenase. 
  • HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. 
  • HIV-1 infection: fooling the gatekeeper. 
  • HIV-1 intrapatient sequence diversity in the immunogenic V3 region. 
  • HIV-1 leader RNA dimeric interface revealed by NMR. 
  • HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. 
  • HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. 
  • HIV-1 neutralizing antibodies: understanding nature's pathways. 
  • HIV-1 neutralizing antibody and approaches to the envelope diversity problem. 
  • HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. 
  • HIV-1 nomenclature proposal. 
  • HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. 
  • HIV-1 sensitivity to zidovudine and clinical outcome in children. 
  • HIV-1 sequence subtype D in the United States. 
  • HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. 
  • HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. 
  • HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. 
  • HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. 
  • HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. 
  • HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. 
  • HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. 
  • HIV-1 vaccines and adaptive trial designs. 
  • HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. 
  • HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. 
  • HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. 
  • HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes. 
  • HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 
  • HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. 
  • HIV-1-specific antibody responses during acute and chronic HIV-1 infection. 
  • HIV-1: is Nef a PAK animal? 
  • HIV-1: nature's master of disguise. 
  • HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 
  • HIV-Host Interactions: Implications for Vaccine Design. 
  • HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. 
  • HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. 
  • HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. 
  • HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. 
  • HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. 
  • HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. 
  • HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. 
  • Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence. 
  • Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. 
  • Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. 
  • Herpesvirus saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual. 
  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. 
  • Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. 
  • Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. 
  • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. 
  • High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. 
  • High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. 
  • High prevalence of PI resistance in patients failing second-line ART in Vietnam. 
  • High throughput functional analysis of HIV-1 env genes without cloning. 
  • High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. 
  • High-Frequency Illegitimate Strand Transfers of Nascent DNA Fragments During Reverse Transcription Result in Defective Retrovirus Genomes. 
  • High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. 
  • High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. 
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. 
  • High-performance virtual screening by targeting a high-resolution RNA dynamic ensemble. 
  • High-resolution deep sequencing reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host ecosystems. 
  • High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. 
  • High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. 
  • Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. 
  • Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. 
  • Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. 
  • Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. 
  • Host controls of HIV broadly neutralizing antibody development. 
  • Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. 
  • How much zidovudine is safe for children with advanced HIV? 
  • Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. 
  • Human Immunodeficiency Virus (HIV)-1 Transmission Among Persons With Acute HIV-1 Infection in Malawi: Demographic, Behavioral, and Phylogenetic Relationships. 
  • Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. 
  • Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. 
  • Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. 
  • Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. 
  • Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. 
  • Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. 
  • Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. 
  • Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. 
  • Human immunodeficiency virus as a prototypic complex retrovirus. 
  • Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. 
  • Human immunodeficiency virus type 1 (HIV-1) induces activation of multiple STATs in CD4+ cells of lymphocyte or monocyte/macrophage lineages. 
  • Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. 
  • Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation. 
  • Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex. 
  • Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. 
  • Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. 
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. 
  • Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. 
  • Human immunodeficiency virus type 1 infection of human monocytes and macrophages does not alter their ability to generate an oxidative burst. 
  • Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. 
  • Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. 
  • Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. 
  • Human immunodeficiency virus type 1 rev protein as a negative trans-regulator. 
  • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. 
  • Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. 
  • Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus Nef use distinct but overlapping target sites for downregulation of cell surface CD4. 
  • Human immunodeficiency virus-1 disease progression in hemophiliacs. 
  • Human immunodeficiency virus. Chaperoning a pathogen. 
  • Human immunodeficiency virus: nuclear RNA export unwound. 
  • Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. 
  • Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection. 
  • Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. 
  • Hyponatremia in pediatric patients with HIV-1 infection. 
  • IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. 
  • IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). 
  • Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. 
  • Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. 
  • Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. 
  • Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. 
  • Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. 
  • Identification of Tat-SF1 cellular targets by exon array analysis reveals dual roles in transcription and splicing. 
  • Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. 
  • Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat. 
  • Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. 
  • Identification of a novel cell attachment domain in the HIV-1 Tat protein and its 90-kDa cell surface binding protein. 
  • Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. 
  • Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. 
  • Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. 
  • Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. 
  • Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. 
  • Identification of cis-acting repressor activity within human immunodeficiency virus type 1 protease sequences. 
  • Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. 
  • Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. 
  • Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. 
  • Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. 
  • Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. 
  • Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. 
  • Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4. 
  • Identification of the activation domain of equine infectious anemia virus rev. 
  • Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. 
  • Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. 
  • Identifying human immunodeficiency virus infection at birth: application of polymerase chain reaction to Guthrie cards. 
  • Immune checkpoint modulation enhances HIV-1 antibody induction. 
  • Immune correlates of vaccine protection against HIV-1 acquisition. 
  • Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. 
  • Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. 
  • Immune-based interventions to prevent postnatal HIV-1 transmission. 
  • Immune-correlates analysis of an HIV-1 vaccine efficacy trial. 
  • Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. 
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. 
  • Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. 
  • Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. 
  • Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. 
  • Immunobiology of the human immunodeficiency virus envelope and its relationship to vaccine strategies. 
  • Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians. 
  • Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. 
  • Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. 
  • Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. 
  • Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. 
  • Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. 
  • Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. 
  • Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. 
  • Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. 
  • Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. 
  • Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. 
  • Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. 
  • Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. 
  • Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. 
  • Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. 
  • Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 
  • Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. 
  • Immunologic targets of HIV infection: T cells. NICHD IVIG Clinical Trial Group, and the NHLBI P2C2 Pediatric Pulmonary and Cardiac Complications of HIV Infection Study Group. 
  • Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. 
  • Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design. 
  • Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. 
  • Immunological mechanisms of inducing HIV immunity in infants. 
  • Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. 
  • Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. 
  • Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. 
  • Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. 
  • Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. 
  • Impact of genotypic resistance testing on physician selection of antiretroviral therapy. 
  • Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. 
  • Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study. 
  • Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. 
  • Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1. 
  • Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL). 
  • Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. 
  • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. 
  • Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. 
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. 
  • Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. 
  • In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. 
  • In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. 
  • In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. 
  • In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. 
  • Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. 
  • Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. 
  • Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. 
  • Increased circulating interleukin-7 levels in HIV-1-infected women. 
  • Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. 
  • Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. 
  • Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. 
  • Increased inflammation but similar physical composition and function in older-aged, HIV-1 infected subjects. 
  • Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. 
  • Increased predominance of HIV-1 CRF01_AE and its recombinants in the Philippines. 
  • Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. 
  • Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. 
  • Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. 
  • Increasing the length of poly-pyrimidine bulges broadens RNA conformational ensembles with minimal impact on stacking energetics. 
  • Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. 
  • Induced Packaging of Cellular MicroRNAs into HIV-1 Virions Can Inhibit Infectivity. 
  • Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. 
  • Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. 
  • Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. 
  • Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. 
  • Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. 
  • Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. 
  • Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. 
  • Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. 
  • Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. 
  • Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. 
  • Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. 
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. 
  • Induction of immunity to human immunodeficiency virus type-1 by vaccination. 
  • Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. 
  • Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. 
  • Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. 
  • Infant HIV-1 vaccines: supplementing strategies to reduce maternal-child transmission. 
  • Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. 
  • Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. 
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. 
  • Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. 
  • Influence of HIV-1 infection and cigarette smoking on leukocyte profile in homosexual men. 
  • Influence of HIV-1 infection and cigarette smoking on leukocyte profiles in homosexual men. The Multicenter AIDS Cohort Study. 
  • Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. 
  • Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. 
  • Influence of dimethylsulfoxide on RNA structure and ligand binding. 
  • Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. 
  • Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1. 
  • Influence of prothymosin-alpha on HIV-1 target cells. 
  • Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. 
  • Inhibition of HIV type 1 infection of mononuclear phagocytes by anti-CD44 antibodies. 
  • Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. 
  • Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. 
  • Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. 
  • Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. 
  • Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. 
  • Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain. 
  • Inhibition of human immunodeficiency virus type 1 replication and cytopathicity by synthetic soluble catecholamine melanins in vitro. 
  • Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. 
  • Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. 
  • Inhibition of productive human immunodeficiency virus-1 infection by cobalamins. 
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. 
  • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. 
  • Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. 
  • Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. 
  • Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. 
  • Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. 
  • Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. 
  • Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
  • Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas. 
  • Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. 
  • Integration of Contact Tracing and Phylogenetics in an Investigation of Acute HIV Infection. 
  • Inter-helical conformational preferences of HIV-1 TAR-RNA from maximum occurrence analysis of NMR data and molecular dynamics simulations. 
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. 
  • Interactions between highly active antiretroviral therapy and over-the-counter agents: a cautionary note. 
  • Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) 
  • Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. 
  • Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. 
  • Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity. Role of signal strength and receptor desensitization. 
  • International network for comparison of HIV neutralization assays: the NeutNet report II. 
  • International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. 
  • Interpretation of western blots of specimens from children infected with human immunodeficiency virus type 1: implications for prognosis and diagnosis. 
  • Intracellular CMTM2 negatively regulates human immunodeficiency virus type-1 transcription through targeting the transcription factors AP-1 and CREB. 
  • Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. 
  • Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. 
  • Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. 
  • Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells. 
  • Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. 
  • Invisible RNA state dynamically couples distant motifs. 
  • Is developing an HIV-1 vaccine possible? 
  • Is there an association between HIV-1 genital shedding and cervical intraepithelial neoplasia 2/3 among women on antiretroviral therapy? 
  • Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. 
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. 
  • Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide. 
  • Isolation, structure, and HIV-1 integrase inhibitory activity of Cytosporic acid, a fungal metabolite produced by a Cytospora sp. 
  • Journey to the center of the cell. 
  • Kernel-based logistic regression model for protein sequence without vectorialization. 
  • Key references in infectious diseases pharmacotherapy. 
  • Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. 
  • Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. 
  • Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. 
  • Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. 
  • Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. 
  • LC-MS Identification, Isolation, and Structural Elucidation of Anti-HIV Tigliane Diterpenoids from Wikstroemia lamatsoensis. 
  • Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. 
  • Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. 
  • Lack of protease inhibitor resistance following treatment failure--too good to be true? 
  • Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. 
  • Latency reversal and viral clearance to cure HIV-1. 
  • Learning to Be Elite: Lessons From HIV-1 Controllers and Animal Models on Trained Innate Immunity and Virus Suppression. 
  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. 
  • Leptospirosis and human immunodeficiency virus co-infection among febrile inpatients in northern Tanzania. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. 
  • Lessons learned from HIV-1 vaccine trials: new priorities and directions. 
  • Lessons learned from human HIV vaccine trials. 
  • Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. 
  • Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks. 
  • LigAmp for sensitive detection of single-nucleotide differences. 
  • Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. 
  • Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. 
  • Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. 
  • Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. 
  • Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. 
  • Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. 
  • Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. 
  • Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. 
  • Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. 
  • Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection. 
  • Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. 
  • Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. 
  • Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. 
  • Lower extremity lymphedema caused by acquired immune deficiency syndrome-related Kaposi's sarcoma: case report and review of the literature. 
  • Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. 
  • Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. 
  • MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. 
  • Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. 
  • Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. 
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. 
  • Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. 
  • Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. 
  • Mapping of pseudouridine residues on cellular and viral transcripts using a novel antibody-based technique. 
  • Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. 
  • Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. 
  • Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. 
  • Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals. 
  • Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study. 
  • Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. 
  • Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. 
  • Measurement of direct and indirect forms of anti-HIV-1 ADCC: implications for other retroviral disease. 
  • Measuring fatigue in people living with HIV/AIDS: psychometric characteristics of the HIV-related fatigue scale. 
  • Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. 
  • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. 
  • Mechanisms by which HIV envelope minimizes immunogenicity. 
  • Medicine. The need for a global HIV vaccine enterprise. 
  • Mg2+-induced variations in the conformation and dynamics of HIV-1 TAR RNA probed using NMR residual dipolar couplings. 
  • Microalbuminuria predicts overt proteinuria among patients with HIV infection. 
  • Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. 
  • Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. 
  • Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. 
  • Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling. 
  • Mitochondrial dysfunction in human immunodeficiency virus-1 transgenic mouse cardiac myocytes. 
  • Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 
  • Mode of delivery and infant respiratory morbidity among infants born to HIV-1-infected women. 
  • Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. 
  • Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. 
  • Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. 
  • Modulation of HIV-1 immunity by adjuvants. 
  • Molecular architecture of native HIV-1 gp120 trimers. 
  • Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. 
  • Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. 
  • Molecular basis of latency in pathogenic human viruses. 
  • Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo. 
  • Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. 
  • Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. 
  • Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. 
  • Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. 
  • Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. 
  • Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. 
  • Molecular targets of anti-HIV-1 triterpenes. 
  • Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. 
  • Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. 
  • Morbidity and mortality among a cohort of HIV-infected adults in a programme for community home-based care, in the Kilimanjaro Region of Tanzania (2003-2005). 
  • Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. 
  • Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges. 
  • Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. 
  • Mucosal human defensins 5 and 6 antagonize the anti-HIV activity of candidate polyanion microbicides. 
  • Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). 
  • Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. 
  • Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. 
  • Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. 
  • Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. 
  • Multiple CTL specificities against autologous HIV-1-infected BLCLs. 
  • Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. 
  • Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. 
  • Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates. 
  • Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. 
  • Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. 
  • Murine CXCR-4 is a functional coreceptor for T-cell-tropic and dual-tropic strains of human immunodeficiency virus type 1. 
  • Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. 
  • Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. 
  • Mutational definition of functional domains within the Rev homolog encoded by human endogenous retrovirus K. 
  • Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. 
  • Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. 
  • Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers. 
  • NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses. 
  • Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. 
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. 
  • Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. 
  • Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. 
  • Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. 
  • Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. 
  • Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. 
  • Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation. 
  • Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. 
  • Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. 
  • Neopterin production by HIV-1-infected mononuclear phagocytes. 
  • Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. 
  • Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. 
  • Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. 
  • Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. 
  • Neutralization epitopes of the HIV-1 primary isolate DH012. 
  • Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. 
  • Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. 
  • Neutralization tiers of HIV-1. 
  • Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. 
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. 
  • Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. 
  • Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. 
  • Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. 
  • Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. 
  • Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? 
  • Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. 
  • Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. 
  • Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. 
  • Neutralizing antibodies take a swipe at HIV in vivo. 
  • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. 
  • Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. 
  • Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. 
  • New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. 
  • New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. 
  • New frontiers of immunotherapy for HIV. 
  • New phorbol ester derivatives as potent anti-HIV agents. 
  • Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. 
  • Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. 
  • Nosocomial infection rate as a function of human immunodeficiency virus type 1 status in hemophiliacs. 
  • Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. 
  • Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. 
  • Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. 
  • Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway. 
  • Nuclear mRNA export: insights from virology. 
  • Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 
  • Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. 
  • Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. 
  • Opportunistic intraocular infections in AIDS. 
  • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. 
  • Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. 
  • Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. 
  • Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. 
  • Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. 
  • Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. 
  • Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. 
  • Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. 
  • Oral SIV, SHIV, and HIV type 1 infection. 
  • Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. 
  • Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. 
  • Origins and evolution of AIDS viruses. 
  • Origins and evolution of AIDS viruses: estimating the time-scale. 
  • Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. 
  • Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. 
  • Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. 
  • Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. 
  • Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. 
  • PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. 
  • Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. 
  • Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. 
  • Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion. 
  • Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? 
  • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. 
  • Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. 
  • Pathogenesis and natural history of HIV infection. 
  • Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. 
  • Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent. 
  • Pediatric HIV infection in Elista, Russia: interventional strategies. 
  • Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. 
  • Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. 
  • Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. 
  • Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission. 
  • Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. 
  • Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. 
  • Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. 
  • Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. 
  • Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. 
  • Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. 
  • Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. 
  • Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. 
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. 
  • Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. 
  • Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. 
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. 
  • Phenotypic properties of transmitted founder HIV-1. 
  • Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. 
  • Phosphorylation of the rev gene product of human immunodeficiency virus type 1. 
  • Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies. 
  • Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O. 
  • Picomolar dichotomous activity of gnidimacrin against HIV-1. 
  • Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. 
  • Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine. 
  • Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. 
  • Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. 
  • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. 
  • Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. 
  • Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. 
  • Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. 
  • Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. 
  • Polyploidy and Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes in Renal Tubule Epithelial Cells. 
  • Polyreactivity and autoreactivity among HIV-1 antibodies. 
  • Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. 
  • Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. 
  • Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. 
  • Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. 
  • Porphyromonas gingivalis-mediated Epithelial Cell Entry of HIV-1. 
  • Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. 
  • Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. 
  • Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. 
  • Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression. 
  • Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. 
  • Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. 
  • Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. 
  • Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. 
  • Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. 
  • Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. 
  • Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. 
  • Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. 
  • Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. 
  • Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. 
  • Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. 
  • Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. 
  • Precise mapping of recombination breakpoints suggests a common parent of two BC recombinant HIV type 1 strains circulating in China. 
  • Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. 
  • Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population. 
  • Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. 
  • Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. 
  • Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. 
  • Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. 
  • Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. 
  • Predictors of glycaemic control among HIV-positive veterans with diabetes. 
  • Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. 
  • Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation. 
  • Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques. 
  • Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. 
  • Preexposure prophylaxis for HIV infection among African women. 
  • Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. 
  • Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon. 
  • Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. 
  • Prevalence and Outcome of HIV-associated Malignancies Among HIV-infected Children Enrolled into Care at Kilimanjaro Christian Medical Center 2006 to 2014: A Hospital-based Retrospective Analytical Study. 
  • Prevalence and predictors of proteinuria in HIV-infected and uninfected pregnant women in Cameroon. 
  • Prevalence of HTLV-I-associated T-cell lymphoma. 
  • Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. 
  • Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. 
  • Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. 
  • Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. 
  • Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. 
  • Principles and applications of a Tat-based assay for analyzing specific RNA-protein interactions in mammalian cells. 
  • Probing Na(+)-induced changes in the HIV-1 TAR conformational dynamics using NMR residual dipolar couplings: new insights into the role of counterions and electrostatic interactions in adaptive recognition. 
  • Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. 
  • Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. 
  • Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. 
  • Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy. 
  • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. 
  • Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. 
  • Progress in HIV-1 vaccine development. 
  • Progress in HIV-1 vaccine development. 
  • Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. 
  • Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. 
  • Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. 
  • Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. 
  • Prospects for vaccine protection against HIV-1 infection and AIDS. 
  • Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. 
  • Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques. 
  • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. 
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. 
  • Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. 
  • Provision of guideline-based care for drug-resistant tuberculosis in South Africa: Level of concordance between prescribing practices and guidelines. 
  • Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. 
  • Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. 
  • Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. 
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. 
  • Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. 
  • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. 
  • R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. 
  • RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. 
  • RAB11FIP5-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. 
  • RNA dynamics by design: biasing ensembles towards the ligand-bound state. 
  • RNA-sequence-mediated gene regulation in HIV-1. 
  • Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. 
  • Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. 
  • Rapid Exchange Between Free and Bound States in RNA-Dendrimer Polyplexes: Implications on the Mechanism of Delivery and Release. 
  • Rapid and accurate determination of atomistic RNA dynamic ensemble models using NMR and structure prediction. 
  • Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. 
  • Rapid freezing of whole blood or buffy coat samples for polymerase chain reaction and cell culture analysis: application to detection of human immunodeficiency virus in blood donor and recipient repositories. The Transfusion Safety Study Group. 
  • Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis. 
  • Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. 
  • Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. 
  • Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. 
  • Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. 
  • Recent progress in immune-based interventions to prevent HIV-1 transmission to children. 
  • Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. 
  • Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. 
  • Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. 
  • Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. 
  • Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. 
  • Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. 
  • Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. 
  • Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. 
  • Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs. 
  • Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. 
  • Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. 
  • Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. 
  • Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. 
  • Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. 
  • Reduction of Stat3 activity attenuates HIV-induced kidney injury. 
  • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. 
  • Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. 
  • Referencing strategy for the direct comparison of nuclear magnetic resonance and molecular dynamics motional parameters in RNA. 
  • Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. 
  • Regulation of HIV-1 gene expression. 
  • Regulation of gene expression in the human immunodeficiency virus type 1. 
  • Regulation of human immunodeficiency virus replication. 
  • Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. 
  • Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. 
  • Relative resistance of HIV-1 founder viruses to control by interferon-alpha. 
  • Reliable genotypic tropism tests for the major HIV-1 subtypes. 
  • Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. 
  • Renal epithelial cells produce and spread HIV-1 via T-cell contact. 
  • Renal epithelium is a previously unrecognized site of HIV-1 infection. 
  • Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. 
  • Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. 
  • Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. 
  • Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. 
  • Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. 
  • Reply to 'Quantification of HIV-1 RNA on Dried Blood Spots' AIDS 24:475-6. 
  • Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. 
  • Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. 
  • Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. 
  • Resistance to neutralizing antibody and expanded coreceptor usage are associated with human immunodeficiency virus type 1 isolates derived from chimpanzees with pathogenic infections. 
  • Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. 
  • Resolving fast and slow motions in the internal loop containing stem-loop 1 of HIV-1 that are modulated by Mg2+ binding: role in the kissing-duplex structural transition. 
  • Resolving sugar puckers in RNA excited states exposes slow modes of repuckering dynamics. 
  • Resolving the motional modes that code for RNA adaptation. 
  • Response to hepatitis B immunization in children with hemophilia: relationship to infection with human immunodeficiency virus type 1. 
  • Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. 
  • Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. 
  • Retroviruses as model systems for the study of nuclear RNA export pathways. 
  • Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. 
  • Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. 
  • Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function. 
  • Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus. 
  • Robust antibody and cellular responses induced by DNA-only vaccination for HIV. 
  • Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. 
  • Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. 
  • Role of HIV membrane in neutralization by two broadly neutralizing antibodies. 
  • Role of Porphyromonas gingivalis outer membrane vesicles in oral mucosal transmission of HIV. 
  • Role of chemokine receptors in HIV-1 infection and pathogenesis. 
  • Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. 
  • Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity. 
  • Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. 
  • Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. 
  • Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. 
  • Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. 
  • Role of ubiquitin-like protein FAT10 in epithelial apoptosis in renal disease. 
  • SARS-CoV-2 and HIV-1 - a tale of two vaccines. 
  • SIVcpz in wild chimpanzees. 
  • SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. 
  • Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. 
  • Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. 
  • Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. 
  • Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. 
  • Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. 
  • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. 
  • Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. 
  • Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. 
  • Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. 
  • Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. 
  • Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. 
  • Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. 
  • Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. 
  • Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. 
  • Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. 
  • Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. 
  • Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. 
  • Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. 
  • Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. 
  • Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces. 
  • Search for the origin of HIV and AIDS. 
  • Seasonal variation in the etiology of bloodstream infections in a febrile inpatient population in a developing country. 
  • Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. 
  • Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. 
  • Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. 
  • Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. 
  • Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. 
  • Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. 
  • Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro. 
  • Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. 
  • Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. 
  • Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. 
  • Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. 
  • Sequence requirements for Rev multimerization in vivo. 
  • Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. 
  • Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. 
  • Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination. 
  • Seroprevalence and seroincidence of HIV-1 in injection drug users using the VA system. 
  • Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania. 
  • Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. 
  • Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. 
  • Sexual abuse of human immunodeficiency virus-positive children. Outcomes for perpetrators and evaluation of other household children. 
  • Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. 
  • Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. 
  • Short communication: characteristics of effective immune control of simian/human immunodeficiency virus in pigtail macaques. 
  • Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. 
  • Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. 
  • Shortening HIV vaccine regimens to achieve high coverage. 
  • Shortening the HIV-1 TAR RNA Bulge by a Single Nucleotide Preserves Motional Modes over a Broad Range of Time Scales. 
  • Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. 
  • Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4+ T Cells. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. 
  • Simultaneous Detection of Major Drug Resistance Mutations of HIV-1 Subtype B Viruses from Dried Blood Spot Specimens by Multiplex Allele-Specific Assay. 
  • Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay. 
  • Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. 
  • Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. 
  • Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. 
  • Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. 
  • Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. 
  • Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. 
  • Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. 
  • Specific activation strategies for amplification of low CTL signals. 
  • Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. 
  • Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. 
  • Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. 
  • Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. 
  • Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. 
  • Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. 
  • Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. 
  • Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. 
  • Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. 
  • Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. 
  • Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. 
  • Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. 
  • Strategies for eliciting HIV-1 inhibitory antibodies. 
  • Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. 
  • Strategies used in the detection of acute/early HIV infections. The NIMH Multisite Acute HIV Infection Study: I. 
  • Streamlined Subpopulation, Subtype, and Recombination Analysis of HIV-1 Half-Genome Sequences Generated by High-Throughput Sequencing. 
  • Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. 
  • Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. 
  • Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. 
  • Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. 
  • Structural and functional analysis of the visna virus Rev-response element. 
  • Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. 
  • Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development. 
  • Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. 
  • Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. 
  • Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. 
  • Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å cocrystal structure of gp120 and M48U1. 
  • Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. 
  • Structural biology: Aerial view of the HIV genome. 
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. 
  • Structural features of an RNA containing the CUGGGA loop of the human immunodeficiency virus type 1 trans-activation response element. 
  • Structural features of the trans-activation response RNA element of equine infectious anemia virus. 
  • Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. 
  • Structural rearrangements in the transmembrane glycoprotein after receptor binding. 
  • Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. 
  • Structure and function of CC-chemokine receptor 5 homologues derived from representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea. 
  • Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. 
  • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. 
  • Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer. 
  • Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. 
  • Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. 
  • Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. 
  • Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies. 
  • Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 
  • Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. 
  • Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. 
  • Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. 
  • Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. 
  • Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. 
  • Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. 
  • Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. 
  • Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth. 
  • Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. 
  • Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. 
  • Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes. 
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. 
  • Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. 
  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. 
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. 
  • Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. 
  • Synergistic enhancement of both initiation and elongation by acidic transcription activation domains. 
  • Synthesis and Structure-Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents. 
  • Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs. 
  • Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. 
  • Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants. 
  • Systematic review of the performance of HIV viral load technologies on plasma samples. 
  • Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis. 
  • Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. 
  • Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. 
  • TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation. 
  • TRIGGERED: could refocused cell signaling be key to natural killer cell-based HIV immunotherapeutics? 
  • Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment. 
  • Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. 
  • Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. 
  • Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. 
  • Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. 
  • Taste and smell losses in HIV infected patients. 
  • Tat-SF1 is not required for Tat transactivation but does regulate the relative levels of unspliced and spliced HIV-1 RNAs. 
  • Tax Induces the Recruitment of NF-κB to Unintegrated HIV-1 DNA To Rescue Viral Gene Expression and Replication. 
  • Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. 
  • Terpenes from Euphorbia antiquorum and Their in Vitro Anti-HIV Activity. 
  • The Bel-1 protein of human foamy virus activates human immunodeficiency virus type 1 gene expression via a novel DNA target site. 
  • The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. 
  • The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. 
  • The HIV-1 Rev protein: prototype of a novel class of eukaryotic post-transcriptional regulators. 
  • The HIV-1 Tat protein: an RNA sequence-specific processivity factor? 
  • The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. 
  • The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field. 
  • The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids. 
  • The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. 
  • The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. 
  • The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. 
  • The antibody response in HIV-1 infection. 
  • The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. 
  • The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. 
  • The design and evaluation of HIV-1 vaccines. 
  • The development of CD4 binding site antibodies during HIV-1 infection. 
  • The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. 
  • The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. 
  • The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. 
  • The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. 
  • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. 
  • The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. 
  • The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. 
  • The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. 
  • The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy. 
  • The humoral response to HIV-1: new insights, renewed focus. 
  • The immune response during acute HIV-1 infection: clues for vaccine development. 
  • The immune response to HIV: implications for vaccine development. 
  • The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees. 
  • The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. 
  • The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. 
  • The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. 
  • The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. 
  • The quest for an antibody-based HIV vaccine. 
  • The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. 
  • The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? 
  • The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. 
  • The role of HIV-DNA testing in clinical practice. 
  • The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. 
  • The role of dynamin in HIV type 1 Env-mediated cell-cell fusion. 
  • The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack. 
  • The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. 
  • The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. 
  • The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. 
  • The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. 
  • The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. 
  • The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. 
  • The variable loop 3 in the envelope glycoprotein is critical for the atypical coreceptor usage of an HIV-1 strain. 
  • Three populations of cells with dendritic morphology exist in peripheral blood, only one of which is infectable with human immunodeficiency virus type 1. 
  • Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. 
  • Thrombotic thrombocytopenic purpura during immune reconstitution. 
  • Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. 
  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. 
  • Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. 
  • Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. 
  • Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. 
  • Timing the ancestor of the HIV-1 pandemic strains. 
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. 
  • Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. 
  • Topology links RNA secondary structure with global conformation, dynamics, and adaptation. 
  • Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. 
  • Towards structural genomics of RNA: rapid NMR resonance assignment and simultaneous RNA tertiary structure determination using residual dipolar couplings. 
  • Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. 
  • Trans-activating rev protein of the human immunodeficiency virus 1 interacts directly and specifically with its target RNA. 
  • Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication. 
  • Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition. 
  • Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner. 
  • Transcriptional network predicts viral set point during acute HIV-1 infection. 
  • Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors. 
  • Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. 
  • Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. 
  • Transforming growth factor beta stimulates the human immunodeficiency virus 1 enhancer and requires NF-kappaB activity. 
  • Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. 
  • Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences. 
  • Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. 
  • Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. 
  • Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. 
  • Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. 
  • Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. 
  • Trichomonas vaginalis as a cause of urethritis in Malawian men. 
  • Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. 
  • Tuberculosis and AIDS. 
  • Tuberculous pericarditis in Tanzanian patients with and without HIV infection. 
  • Two DNA polymerases: HIV reverse transcriptase and the Klenow fragment of Escherichia coli DNA polymerase I. 
  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. 
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. 
  • Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. 
  • Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. 
  • Tyrosine-sulfate isosteres of CCR5 N-terminus as tools for studying HIV-1 entry. 
  • Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'. 
  • Understanding the characteristics of nonspecific binding of drug-like compounds to canonical stem-loop RNAs and their implications for functional cellular assays. 
  • Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. 
  • Unsung hero Robert C. Gallo. 
  • Unusual pattern of enhancement in cryptococcal meningitis: in vivo findings with postmortem correlation. 
  • Unusual structure of the human immunodeficiency virus type 1 trans-activation response element. 
  • Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 
  • Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation. 
  • Using microcantilever deflection to detect HIV-1 envelope glycoprotein gp120. 
  • Utility of rapid antibody tests to exclude HIV-1 infection among infants and children aged <18 months in a low-resource setting. 
  • Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. 
  • V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. 
  • V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. 
  • Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. 
  • Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. 
  • Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. 
  • Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. 
  • Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. 
  • Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. 
  • Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. 
  • Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. 
  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. 
  • Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. 
  • Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. 
  • Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. 
  • Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. 
  • Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. 
  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. 
  • Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide. 
  • Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. 
  • Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. 
  • Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. 
  • Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks. 
  • Validation, performance under field conditions, and cost-effectiveness of Capillus HIV-1/HIV-2 and determine HIV-1/2 rapid human immunodeficiency virus antibody assays using sequential and parallel testing algorithms in Tanzania. 
  • Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. 
  • Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. 
  • Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. 
  • Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. 
  • Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. 
  • Viral Epitranscriptomics. 
  • Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. 
  • Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. 
  • Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. 
  • Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy. 
  • Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. 
  • Virology. New trick from an old foe. 
  • Visna virus encodes a post-transcriptional regulator of viral structural gene expression. 
  • Visualizing spatially correlated dynamics that directs RNA conformational transitions. 
  • Visualizing transient low-populated structures of RNA. 
  • What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. 
  • Wide variation in the multiplicity of HIV-1 infection among injection drug users. 
  • Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. 
  • [Design, synthesis and evaluation of novel 2H-1, 4-benzodiazepine-2-ones as inhibitors of HIV-1 transcription]. 
  • chngpt: threshold regression model estimation and inference. 
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. 
  • iRED analysis of TAR RNA reveals motional coupling, long-range correlations, and a dynamical hinge. 
  • mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. 
  • Δ(9)-Tetrahydrocannabinol treatment during human monocyte differentiation reduces macrophage susceptibility to HIV-1 infection. 
  • λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Cade, William Todd, Professor of Orthopaedic Surgery, Orthopaedics, Physical Therapy
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Cunningham, Coleen Kathryn, Adjunct Professor in the Department of Pediatrics, Pediatrics
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Katz, David F., Nello L. Teer, Jr. Distinguished Professor of Biomedical Engineering, in the Edmund T. Pratt, Jr. School of Engineering, Biomedical Engineering
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Immunology
  • Luftig, Micah Alan, Associate Professor of Molecular Genetics and Microbiology, Immunology
  • Moody, Michael Anthony, Professor of Pediatrics, Immunology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Immunology